Target
$253.52 → $256.45
Current stock research snapshot · 7/12/26 45 days old
DHRDanaher
Investment conviction●●○○○2 of 5 · current snapshot
Research target$256.45Current stock price target
Investment thesis statusINTACTLast reviewed 7/12/26
Market cap$134.62BSnapshot value · 7/12/26
Research history
See all DHR changes ↗What changed
Thesis status
STRENGTHENED → INTACT
Target
$253.51 → $253.52
Diversified life-science + diagnostics conglomerate. Cytiva/Pall bioprocessing gives Manufacture-layer exposure; Beckman/SCIEX/Leica give Measure exposure. Paid on volume across the whole competition.
Bioprocess cycle recovery (consumables growing ~10% YoY post-destocking); Masimo-adjacent acquisition expands monitoring; Danaher Business System margin execution.
Integration risk from acquisition strategy; bioprocess cyclicality (2023-24 destocking redux); segment dilution — bioprocess is a tailwind, not the whole thesis.
Bullish — Renaissance added position Q2/26; +8% weekly move Aug 22 2026 [X search Aug 2026]
Snapshot · 7/12/26🟢 Lean-Bull · ins-$0.2M · 13F 17+/8-×0.5 · short↓0.19
Snapshot · 7/12/26